ArticleBiomarker insights2026
Multi-Target Cardioprotective Potential of
Article in Biomarker insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial infarction (MI), especially its adrenaline-induced myocardial injury, remains a leading cause of global mortality, often resulting in irreversible cardiac damage and heart failure due to stress cardiomyopathy. Objectives: Design: The current study investigated the predicted cardioprotective potential of Method: Thirty bioactive compounds from the whole plant were identified. Of these, eight lead phytochemicals, including neo-clerodane diterpenoids and phytoecdysteroids, were subjected to ADMET screening. They passed the screening showing desirable drug-like properties. From network pharmacology analysis, 278 overlapping targets were identified between MI-associated genes and those in the ingredient database. The top three hub proteins were AKT1 (node degree 151), GAPDH (150), and TNF (149), respectively. Results: GO and KEGG enrichment analyses showed that these genes were primarily involved in the regulation of the apoptotic process, oxidant stress response, and the PI3K-Akt, TNF, and MAPK signaling pathways. Molecular docking (MOE 2019.01) results show that Ivain II showed the strongest binding affinity score with value of -9.42 kcal/mol for GAPDH and TNF-α through multiple hydrogen bonds, lipophilic contacts, and π-alkyl interactions. Conclusion: These findings provide the first computational mechanistic insight into the predicted multi-target cardioprotective potential of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.